Early Recognition of Pyoderma Gangrenosum in Pregnancy May Prevent Complications: Study

Written By :  Dr Riya Dave
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-07-18 15:15 GMT   |   Update On 2025-07-18 15:16 GMT
Advertisement

A new study published in the Journal of Drugs in Dermatology has found that heightened awareness and early diagnosis of pyoderma gangrenosum (PG) during pregnancy can avoid severe maternal and fetal complications. The study was conducted by Gretchen D. and colleagues. The results highlight the critical nature of precise diagnosis and tailored treatment in enhancing outcomes for both mother and infant.

The systematic review of PubMed, Embase, and Web of Science articles found 62 relevant publications describing 63 cases of PG developed during pregnancy or within six weeks postpartum. PG is defined by the acute development of progressive skin ulcers and typically occurs in association with autoimmune conditions, although most of the 55 reviewed cases (87.3%) had no underlying inflammatory bowel or rheumatologic disease. These observations point out that PG may arise in isolation of other disorders in the systemic system, especially at the immunologically dynamic stage of pregnancy.

Advertisement

One of the major concerns noted in the study was the initial misdiagnosis rate. Of 63 patients, 45 (71.4%) were initially misdiagnosed, resulting in delays in starting proper therapy and, on occasion, in the need for unnecessary surgical procedures. PG was frequently mistaken for infectious ulcers or surgical wound complications, which highlights the importance of clinical attention and multidisciplinary approach in the case of non-healing ulcer in pregnancy. Misdiagnosis leads to inappropriate therapy, which aggravates the lesion and also poses greater risk of obstetric procedures.

Key findings

  • Management-wise, systemic corticosteroids were used most commonly, being administered in 56 out of 63 cases (88.9%).

  • This confirms the key place of immunosuppression in PG therapy.

  • 21 patients (33.3%) were treated with cyclosporine, either as a first-line treatment or in steroid-resistant cases.

  • Though there was concern for fetal safety, these therapies were well tolerated and effective in general.

  • Most importantly, success with therapy depended more on the timing and accuracy of diagnosis than on the immunosuppressive agent used.

  • Emergency Cesarean section was the most frequently reported pregnancy complication, being seen in 19 cases.

The research supports that pyoderma gangrenosum in pregnancy is frequently misdiagnosed and undertreated, with resultant poor maternal and fetal outcomes. Heightened clinical awareness, particularly in the presence of uncharacteristic ulcerative lesions, is critical to enhance prognosis. Immunological changes in pregnancy could make some women susceptible to PG even without pre-existing systemic disease.

Reference:

Pyoderma gangrenosum in pregnancy: A systematic review of clinical characteristics, treatment outcomes, and maternofetal implications. (2025, June 30). JDDonline - Journal of Drugs in Dermatology. https://jddonline.com/articles/pyoderma-gangrenosum-in-pregnancy-systematic-review-of-clinical-characteristics-treatment-outcomes-maternofetal-implications-S1545961625P8843X?mkt_tok=NzkzLUxNVC0yMDcAAAGbbFd0_9l3nsoCbWRi0JIkhQ1QzCyID4HrQfW19L2JGk3VpkVUWRB8ij4tE5-EsSFXBUtZgJuwlM0-tl2HmU8d-MTWj6zzKyrFiU0-D0s


Tags:    
Article Source : Journal of Drugs in Dermatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News